Factors Associated with Treatment Compliance of Extrapulmonary Tuberculosis Patients at the End of Intensive Phase
DOI:
https://doi.org/10.3329/jom.v26i2.84355Keywords:
DOTS, Compliance, EPTB, TuberculosisAbstract
Introduction: Tuberculosis (TB) remains a global health threat, with extrapulmonary tuberculosis (EPTB) posing particular challenges in diagnosis and treatment compliance.This study investigated factors affecting compliance among EPTB patients in Bangladesh, with a focus on those receiving treatment under the Directly Observed Treatment, Short-course (DOTS) strategy.
Methodology: A cross-sectional study was conducted, collecting data from 209 individuals with EPTB using a semi-structured questionnaire at 12 DOTS centers in the Dhaka division. Patients aged 18 and older, regardless of gender, with EPTB were included. Those who were being re-treated or had serious illnesses like human immunodeficiency virus (HIV), chronic kidney disease, stroke, cancer, or cardiovascular disease (CVD) were excluded.Treatment compliance was measured by adherence to prescribed treatment, including the avoidance of missing doses, at the end of the intensive phase. Those who complied with treatment were compared with those who did not comply.
Results: Of 209 respondents, the level of treatment compliance to EPTB treatment was 96% and cervical lymph node was found to be affected mostly (30%) by tuberculosis. Mean age, age group, belief about death that can result if not treated, and satisfaction from counseling by healthcare providers were significantly associated with treatment compliance (p <0.05). On binary logistic regression analysis, joint family type (AOR = 65.802; 95%CI:.58-1865.504) was independently associated with treatment compliance.
Conclusion: The compliance among the extrapulmonary tuberculosis patients attending DOTS centers was 96%. The study found that mean age, age group, belief about EPTB that can result in death if not treated, satisfaction with counseling from the health care provider were associated with treatment compliance with anti-TB treatment among people with EPTB.
J MEDICINE 2025; 26(2): 101-109
Downloads
45
20
Downloads
Published
How to Cite
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).